InMed Pharmaceuticals Incorporated (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, announced on Friday that it has named Dr Sazzad Hossain, PhD, MSc as a new member of its Scientific Advisory Board.
Dr Hossain has announced his retirement as chief scientific officer. Dr Eric C Hsu, PhD, vice president, Pre-Clinical Research & Development, will continue to lead the company's scientific R&D programs.
Dr Hossain said, 'InMed's continued success in developing cannabinoids to treat serious diseases is vital to me. Unfortunately, given recent personal health concerns, I wish to modify my role to that of a scientific advisor. I look forward to continuing my involvement with the entire team at InMed. I believe the Company is in a very strong position to advance important potential treatments to patients with high unmet medical needs.'
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer